Clinical Trial Detail

NCT ID NCT02853344
Title Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

clear cell renal cell carcinoma

renal cell carcinoma

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.